NKCL Bio Group and Labelle Clinic of Gwang-ju,
Korea, had signed MOA on April 28th, agreeing upon delivering NK cell
treatment.
Labelle Clinic has 4 storied building with
organized facilities. With director Park Tae-ho, many medical professionals and
staff members are working in.
Especially, Labelle Clinic is a registered hospital
for foreign patients, making it suitable and ready for global medical market.
NKCL Bio Group’s Chairman Shin Dong-Hwa and Labelle
Clinic’s Park Tae-ho had shared visions of NKCL’s technology and its future in global
market and discussed potential areas and directions where two parties can
promote synergy.
NKCL Bio group continues selecting partners for
NK cell treatment and launching products to focus on NKCL Branding.
NKCL Bio Group will launch various
Bio-Program that enhances immunity with NK cells. Following NK Rest Brain, NKCL
will launch ‘NK Bio Blue Recombination Cream Set’ which has excellent effects
on various skin immunity disorders such as atopy and psoriasis, as well as ‘NK
Cordycep Gold 300’, anti-cancer functional food which contains large amount of
Cordycepin, the main ingredient of Cordyceps Militaris. Also, there is ‘NK
immune series’ skin-care that enhances immunity of the skin and ‘NK Complete
immune compact cushion’ that perfectly covers blemish of the skin. Last but not
least, there will be ‘NK DNA Navigator’ that analyze the user’s DNA. On the
first half of 2020, 20 different products will be launched for 7 different
brands.
In May, the construction of R&D center
and the new headquarter is in full swing prior to the relocation. In June and
August, the headquarter will be relocated and the GMP automated cultivation
system will be completed respectively. Spokesman from NKCL Bio Group had said
the company will launch various high-quality products that matches its catch
phrase, ‘Personalized Immune Care Platform’ and they expect greater growth at
this time when the importance of immunity is being maximized through COVID-19.